Lancashire and South Cumbria
Formulary
Formulary
3 Respiratory system
When prescribing inhalers the drug, device (e.g. MDI, Easibreathe, Autohaler, Accuhaler), strength (micrograms per inhalation), number of puffs per dose and frequency MUST be specified
03-01-01-01 Short-acting beta2 agonists
Dry Powder Inhalers (DPIs) are, where clinically appropriate, the preferred devices to be used. In COPD combination inhalers should be used wherever possible.
| Salbutamol |
|
Formulary
|
Nebuliser solution 2.5mg/2.5mL, 5mg/2.5mL
Metered dose inhaler 100micrograms/inhalation
Easyhaler® 100micrograms inhalation
Easyhaler® 200micrograms inhalation
Ventolin Accuhaler® 200micrograms/inhalation
Airomir 100µg / inhalation
Airomir 100µg / inhalation Autohaler
Salamol CFC-Free MDI Inhaler 100mcg
First choice reliever in fixed dose regimen. |
 LSCMMG: Asthma Treatment Guideline for Adults (aged 12 and over) |
|
Links
NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma- Asthma action plan child: Asthma UK
- Asthma management plan: Asthma UK
- LSCMMG: Asthma Treatment Guideline for Adults (aged 12 and over)
- LSCMMG: Asthma Treatment Guideline for Adults (aged 12 and over)
- LSCMMG: Asthma Treatment Guideline for Children
- LSCMMG: COPD Desktop Guideline
- MART asthma plan
- MHRA Drug Safety Update :Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists
- MHRA: Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects
- MHRA: Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines
- NICE NG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NICE NG209: Tobacco: preventing uptake, promoting quitting and treating dependence
- NICE NG80:Asthma: diagnosis, monitoring and chronic asthma management
- NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
- NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)